Skip to main content

Advertisement

Log in

Bladder cancer

Advancing NMIBC treatment beyond current BCG formulations

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Multiple BCG strains are used for intravesical instillation treatment of non-muscle-invasive bladder cancer but no large randomized studies comparing these strains are available. To enable creation of new BCG-related agents that overcome the instabilities of the current formulations, molecular examination of BCG's mechanisms of action is required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology, bladder cancer (2016 version 2). NCCN https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (2016).

  2. Hinotsu, S. et al. Sustained prophylactic effect of intravesical bacille Calmette–Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 67, 545–549 (2006).

    Article  Google Scholar 

  3. Witjes, J. A. et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol. Oncol. 34, 484.e19–484.e25 (2016).

    Article  Google Scholar 

  4. Hinotsu, S., Kamatani, N., Ratliff, T. L. & Akaza, H. A systematic review and meta-analysis on the safety and efficacy of different strains of Mycobacterium bovis bacillus Calmette–Guérin for non-muscle invasive bladder cancer in Japan and US. Eur. J. Oncol. Pharm. 8, 8–18 (2014).

    Google Scholar 

  5. Gan, C., Mostafid, H., Khan, M. S. & Lewis, D. J. BCG immunotherapy for bladder cancer — the effects of substrain differences. Nat. Rev. Urol. 10, 580–588 (2013).

    Article  CAS  Google Scholar 

  6. National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology, bladder cancer (Asia consensus statement 2016 version 1). NCCN https://www.nccn.org/professionals/physician_gls/PDF/bladder-asia.pdf (2016).

  7. Morales, A. & Cohen, Z. Mycobacterium phlei cell wall–nucleic acid complex in the treatment of non-muscle invasive bladder cancer unresponsive to bacillus Calmette–Guérin. Expert Opin. Biol. Ther. 16, 273–283 (2016).

    Article  CAS  Google Scholar 

  8. Miyazaki, J. et al. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette–Guérin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. BJU Int. 108, 1520–1526 (2011).

    Article  CAS  Google Scholar 

  9. Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119–3125 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hideyuki Akaza.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akaza, H. Advancing NMIBC treatment beyond current BCG formulations. Nat Rev Urol 14, 12–13 (2017). https://doi.org/10.1038/nrurol.2016.248

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2016.248

  • Springer Nature Limited

Navigation